Vaccines

COVID-19 vaccination rates were higher in counties with more primary care physicians, suggesting doctors are in unique positions of trust with their patients and can encourage vaccination.

A process known as thin film freezing can convert existing therapies into powder that offers another delivery solution and may help alleviate storage challenges in developing countries.

Trying to increase COVID-19 vaccination rates in these populations has been challenging. In an attempt to do so, a randomized clinical trial across 133 skilled nursing facilities (SNFs) was performed.

Intranasal COVID-19 vaccines aren’t just needle and pain-free—they may also be more effective at protecting against current and future variants.

Omicron's numerous spike protein mutations caused mass concern, but one research team hypothesizes that its mutations are largely documented and thus susceptible to COVID-19 vaccination.

A recent study in Guangdong, China, confirmed vaccine effectiveness of inactivated COVID-19 vaccines against the Delta variant of COVID-19.

Not all people unvaccinated against COVID-19 people are actively avoiding the vaccine. A new study shows that Black people were vaccinated at lower rates than White people in the US early on, even after they indicated they were willing to get the shot. The study’s authors explain the reasons behind this.

During spring 2021, when Alpha was the dominant COVID-19 variant, a midsized Midwestern university’s vaccination initiative was associated with a significant decrease in COVID-19 infections.

Low COVID-19 vaccination rates among Hispanic populations may be due to limited vaccine information available in Spanish.

The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.

Triple COVID-19 vaccination or infection-plus-vaccination hybrid immunity induces high-quality antibodies, capable of neutralizing even the Omicron variant.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted 13-0 in favor of the vaccine for adults.

Pfizer-BioNTech asked the FDA for Emergency Use Authorization to administer its COVID-19 vaccine to children 6 months-5 years of age, despite evidence that 2 vaccine doses may not be enough to elicit the desired immune response.

Health care workers in Taiwan who were previously infected with SARS-CoV-1 showed a more robust antibody response to the AstraZeneca COVID-19 vaccine, a new study found.

Backed by solid data, clinicians can work to overcome vaccine hesitancy due to fears about negative pregnancy outcomes.

Moderna recipients were less likely to experience COVID-19 breakthrough infections and hospitalizations than the Pfizer-BioNTech group.

The company’s Spikvax vaccine was approved based on its submission that included efficacy and safety data approximately 6 months after second dose.

A booster vaccination increases protection against COVID-19 whether homologous or heterologous with the primary vaccine.

Before children were authorized to receive the Pfizer-BioNTech vaccine, living with 1-2 fully vaccinated parents significantly reduced children’s risk of COVID-19 infection during the Alpha and Delta periods.

The first doses of Moderna and IAVI’s mRNA HIV vaccine have been administered in the phase 1 IAVI G002 clinical trial.

The expectation of COVID-19 vaccination side effects may be leading some placebo recipients to report adverse events in vaccine trials.

Experiencing myocarditis after COVID-19 mRNA vaccination is rare, but more likely among persons under 24 years and male.

A third dose of the Pfizer-BioNTech or AstraZeneca mRNA COVID-19 vaccines produced sufficient neutralizing antibody titers against the Omicron variant.

The CDC reported that post-infection immunity paired with COVID-19 vaccination was very protective against the Delta variant.

“Memory” CD4+ and CD8+ T cells may explain why Omicron causes less severe disease than previous COVID-19 variants.

An Israeli study is the first to administer 4 COVID-19 shots, but the boosted antibodies may still not be enough to prevent Omicron breakthrough infections.

Even if they did not experience severe symptoms, unvaccinated people who contract COVID-19 while pregnant are more likely to have poor birth outcomes.

Pfizer reports positive top-line results from a phase 3 study that simultaneously administered Prevnar 20 and its COVID-19 vaccine in older adults.

A model simulated the efficacy of the US’s COVID-19 vaccine rollout, measuring its correlation with reduced hospitalizations and deaths.

Heterologous vaccine intervention (HVI), receiving immune-boosting vaccinations other than a COVID-19 shot, may alleviate COVID-19 case burdens.